CelLBxHealth plc Reports Q3 2026 Trading Update and Financial Outlook

CelLBxHealth plc reported £0.3 million in new business for Q3 2026, a threefold increase from the previous year. The company reduced its year-to-date cash operating loss by approximately 60% to £4.0 million. Management forecasts FY 2026 revenues of £1.8 million, a 29% increase over FY 2025, and projects FY 2027 revenues between £3.0 million and £4.0 million. As of September, CelLBxHealth held £1.4 million in cash and expects an additional £0.8 million from an R&D tax credit.